Egetis Therapeutics AB (publ) (STO:EGTX)
Sweden · Delayed Price · Currency is SEK 9.93
-0.02 (-0.20%)
Oct 13, 2026, 1:49 PM CET
Egetis Therapeutics AB Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Egetis Therapeutics AB stock has a consensus rating of "Buy" and an average price target of kr 18.33. The average 1-year stock price forecast is 84.59% higher than the current stock price, while the lowest is kr 4.30 (-56.70%) and the highest is kr 33.00 (+232.33%).
Price Target: kr 18.33 (+84.59%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Egetis Therapeutics AB stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains kr 23.00 → kr 33.00 | Buy | Maintains | kr 23.00 → kr 33.00 | +232.33% | Sep 29, 2026 |
Financial Forecast
Revenue This Year
537.63M
from 62.40M
Increased by 761.59%
Revenue Next Year
510.48M
from 537.63M
Decreased by -5.05%
EPS This Year
0.46
from -0.90
EPS Next Year
-0.22
from 0.46
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.